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Conclusion: Pemetrexed 900 mg/m2 did not improve survival, progres-
sion-free survival or tumor response over pemetrexed 500 mg/m2 for 
patients with platinum-pretreated advanced NSCLC patients. Certain 
toxicities and clinical sequelae were more frequent in the high dose 
group. Pemetrexed 500 mg/m2 iv q3week should be considered the 
standard dose for second-line treatment of NSCLC.
Maximum CTC Toxicity, Grade 3/4, Occurring in  
> 5% Patients in Either Arm, Regardless of Causality
P 500 N=290 P 900 N=240*
Neutropenia 3.4 7.9
Anemia 4.5 5.8
Thrombocytopenia 2.8 5.4
Fatigue 7.9 11.3
Dyspnea 5.2 5.4
Infection without neutropenia 5.2 6.3
*Safety data for the 51 pts who switched from P 900 to P 500 are not shown here.
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Background: Pemetrexed has shown activity in non-small cell lung 
cancer (NSCLC), both as single drug and in combination with plati-
nums. A prospective, randomized, multicentre study was conducted 
to compare pemetrexed + carboplatin (PC) with a standard regimen, 
gemcitabine + carboplatin (GC).
Methods: Chemonaive patients with veriﬁed NSCLC, stage IIIB (ineli-
gible for curative radiotherapy) or stage IV, WHO performance status 
(PS) 0-2, adequate hematology and calculated creatinine-clearance ≥ 
45 ml/min were eligible. All patients were supplemented with folic acid 
0.4 mg OD and vitamin B12 1 mg IM every 9 weeks, from ≥ 5 days 
before and through the treatment period. Patients were randomized to 
receive either pemetrexed 500 mg/m2 + carboplatin AUC=5 (Calvert’s 
formula) day 1 or gemcitabine 1000 mg/m2 day 1 & 8 + carboplatin 
AUC=5 (Calvert’s formula) day 1. Maximum 4 courses were given 
every 3 weeks. Primary endpoints were deﬁned as global health, nau-
sea/vomiting, dyspnea and fatigue measured by the EORTC QLQ-C30 
and LC13 before every cycle and until 11 weeks after chemotherapy. 
Secondary endpoints were overall survival (OS) and toxicity measured 
by the CTCAE v3.0. Stratiﬁcation was done for age (<75 vs ≥75 years), 
stage (IIIB vs IV) and PS (0-1 vs 2). 190 evaluable patients in each arm 
were required to detect a 15 % improvement on predeﬁned QoL param-
eters with an α of 0.05 and β of 0.80. A loss to follow up of maximum 
15 % was expected.
Results: 446 patients were enrolled from Apr 05 - Jul 06. The two arms 
were well balanced with respect to age, gender, stage, PS and histologi-
cal classiﬁcation. 423 patients were eligible for the primary QoL-analy-
sis and analyses on toxicity (patients who received ≥1 cycle of chemo-
therapy). There were no statistical signiﬁcant differences in mean score 
of the primary endpoints between the treatment arms. No difference in 
grade 3-4 anemia was observed (13 % vs. 12 %). Signiﬁcantly more 
patients in the GC arm experienced grade 3-4 thrombocytopenia (57 % 
vs. 24 %, p<.001), leucopenia (46 % vs. 22 %, p<.001) and granulocy-
topenia (51 % vs 39 %, p=.027). More patients in the GC arm received 
transfusion of platelets (9 % vs. 3 %, p=.007). No difference in the 
frequency of neutropenic fever was recorded. The ﬁnal OS analyses 
will be presented at the IASLC World Conference.
Conclusions: No differences were detected between the two arms 
with respect to the primary QoL outcome. However, patients in the PC 
arm experienced signiﬁcantly less toxicity with respect to leucopenia, 
granulocytopenia and thrombocytopenia.
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Background: Vinﬂunine is a novel microtubule inhibitor obtained by 
semi-synthesis using superacidic chemistry to selectively modify the 
catharanthine moiety of Vinca alkaloid with clinical activity in NSCLC 
(J. Bennouna, BJC, 2006). Single-agent efﬁcacy and safety of VFL and 
docetaxel (DTX) were compared in second line NSCLC. 
Methods: Open-label, multi-centre, randomised, phase III study in 
platinum pre-treated advanced/metastatic NSCLC pts. At least 275 pts 
were to be randomised by arm to receive VFL (320mg/m2, 20-min IV 
infusion) or DTX (75mg/m2, 1-hour IV infusion with dexamethasone 
over 3 days) every 3 weeks. The primary objective was to compare 
progression free survival (PFS), with a non-inferiority analysis based 
on a 10% difference (types I and II error rates: 5%, 20%), response and 
safety were assessed according RECIST and NCI CTC (version 2.0) 
respectively. Patient’s beneﬁt was also evaluated. From 06/03 to 03/05, 
551 pts were randomised (VFL: 274; DTX: 277) and 547 treated (411 
men, 136 women; median age 61 years [range 22-83]; ECOG PS 0-1: 
89%; metastatic: 90%). All pts were platinum pre-treated, in combina-
tion with a vinca alkaloid (22%), paclitaxel (21%), or gemcitabine 
(48%). A total of 950 [1-20] and 1025 [1-18] cycles were given with 
VFL and DTX respectively. Grade 3/4 toxicities: neutropenia (33% 
v 30%), anaemia (8% v 3%), thrombocytopenia (2% v <1%), febrile 
neutropenia (3% v 5%), fatigue (11% v 6%), vomiting (2% v 1%), 
abdominal pain (4% v <1%), constipation (7% v <1%) resulting in 
low toxicity in both arms. Alopecia (20% v 35%), nail disorders (1% v 
6%), injection site reaction (25% v 1%), peripheral neuropathy (11% v 
15%), diarrhoea (6% v 12%) were observed. Efﬁcacy: All efﬁcacy end-
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points were similar: median PFS (2.3 v 2.3 months, hazard ratio: 1.004 
[0.841-1.199]), response rate (4.4% v 5.5%), stable disease (36.0% v 
39.6%), median overall survival (6.7 v 7.2 months, hazard ratio: 0.973 
[0.805-1.176]). Clinical beneﬁt was a composite endpoint based on PS, 
weight, PPI, analgesic consumption, dyspnoea and cough; the primary 
endpoint of clinical beneﬁt analysis was the rate of clinical beneﬁt 
responders, deﬁned as those patients who demonstrated improvement 
in at least one of these parameters, without deterioration in any other 
parameter, and conﬁrmed once at least three weeks later. No signiﬁcant 
difference was observed in the rate of clinical beneﬁt between the vin-
ﬂunine arm (31 responders, 13.1%, 95% CI 9.1-18.0) and the docetaxel 
arm (39 responders, 15.5%, 95% CI 11.3-20.6: c2, p=0.4389). 
Conclusion: Vinﬂunine 320 mg/m2 every 3 weeks was found to be 
similar in terms of efﬁcacy to docetaxel 75 mg/m2 every 3 weeks in 
patients previously treated with a platinum-containing regimen for 
advanced NSCLC patients. Clinical beneﬁt was also comparable for the 
two study treatments. Low, manageable but different toxicity proﬁles 
were observed in either arm allowing a good median relative dose in-
tensity > 98%. Therefore, vinﬂunine offers a new and useful alternative 
for patients suffering from advanced NSCLC in second line setting.
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Background: Platinum-based chemotherapy doublets represent the 
standard ﬁrst-line treatment of patients with locally advanced or 
metastatic non-small cell lung cancer (NSCLC), although toxicity is 
common. Several randomized trials trying to assess whether non-plati-
num combinations were as effective as platinum-based ones yielded 
conﬂicting results. Moreover, another not completely solved question 
is whether triplet regimens could be more effective than chemotherapy 
doublets. This 2 x 2 factorial trial aimed at answering both questions: 
(1) the role of replacing cisplatin (P) with vinorelbine (N), (2) the role 
of adding a third agent, ifosfamide (I), in a chemotherapy doublet with 
gemcitabine (G). Primary endpoint was overall survival (OS). Second-
ary endpoints were response rate (RR), progression-free survival (PFS) 
and toxicity.
Methods: Patients with stage IIIB or IV NSCLC were randomly as-
signed to one of four ﬁrst-line regimens: gemcitabine 1250 mg/m2 on 
days 1, 8 plus cisplatin 80 mg/m2 on day 1 (GP); gemcitabine 1250 
mg/m2 on days 1, 8 plus vinorelbine 25 mg/m2 on days 1, 8 (GN); gem-
citabine 1000 mg/m2 on days 1, 8 plus ifosfamide 2 g/m2 on day 1 plus 
cisplatin 80 mg/m2 on day 1 (GIP); gemcitabine 1000 mg/m2 on days 1, 
8 plus vinorelbine 25 mg/m2 on days 1, 8 plus ifosfamide 3 g/m2 on day 
1 (GIN). Treatments were repeated every 3 weeks for a maximum of 6 
cycles. Considering the 2 x 2 trial design, two comparisons have been 
performed: (1) N-containing vs P-containing regimens [GN and GIN vs 
GP and GIP] and (2) I-triplets vs I-non containing doublets [GIN and 
GIP vs GN and GP]. 
Results: From 10/2001 to 07/2006, a total of 433 patients were 
randomized. The patients characteristics were as follows: 72% males, 
with median age of 63 years (range of 29-79), 40% adenocarcinomas, 
71% stage IV and 53% with ECOG performance status of 0. About 
the comparison (1), RR was 25.6 vs 36.3% (p = 0.032), PFS 5.0 vs 6.5 
months (p = 0.239) and OS 11.1 vs 9.8 months [Hazard Ratio (HR) = 
1.04; 95% C.I.: 0.82-1.33; p = 0.719] for N-containing vs P-contain-
ing regimens, respectively. About the comparison (2), RR was 29.1 vs 
32.8% (p = 0.471), PFS 6.5 vs 5.5 months (p = 0.519) and OS 10.8 vs 
9.8 months (HR = 0.95; 95% C.I.: 0.74-1.21; p = 0.705) for I-triplets vs 
I-non containing doublets, respectively. Grade 3-4 anaemia, leucopenia 
and thrombocytopenia were signiﬁcantly more frequent in P-containing 
regimens; only grade 3-4 leucopenia was more common in I-triplets. 
Concerning non-haematological toxicity, only grade 3-4 nausea-vom-
iting was signiﬁcantly increased in P-containing regimens; no other 
statistically signiﬁcant difference in toxicity was observed. 
Conclusions: Results of this unplanned preliminary analysis indicate 
that replacing P with N or the addiction of I to a chemotherapy doublet 
regimen did not improve OS in the treatment of stage IIIB-IV NSCLC 
patients. However, P-containing regimens showed a statistically signiﬁ-
cant advantage in RR over P-free chemotherapy. 
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Background: Chemotherapeutic response rate would be different by 
the ethnic background. This is a randomized prospective trial of three 
cisplatin-based chemotherapeutic regimens in Korean patients with 
advanced non-small-cell lung cancer.
Methods: A total of 333 patients with advanced non-small cell lung 
cancer were randomly assigned to one of the three regimens of 3-
weekly cycle: cisplatin of 60 mg/m2 on day 1 with docetaxel of 75mg/
m2 (DP) or paclitaxel of 130 mg/m2 (TP) on day 1, or gemcitabine of 
1200mg/m2 on day 1 and 8 (GP). After 2~3 cycles of chemotherapy, 
non-responding patients were crossly assigned to the second-line 
monotherapy of either docetaxel or gemcitabine.
Results: There was no signiﬁcant difference in sex, stage, and perfor-
mance status (PS) score, number of cycles and delivered dose inten-
sity between the 3 groups. Three fourths of the patients had stage IV 
disease and one fourth showed ECOG PS score of 2. Mean cycle of 
the ﬁrst-line chemotherapy was 3.4, and the relative dose intensity was 
97%. The overall response rate was 41.8%, with a median survival of 
328 days (95% CI: 271~385) and median progression free survival of 
139 days (95% CI: 111~167 days). The response rate and progression 
free survival did not differ among the 3 groups. The ﬁrst-line treatment 
